Insider Trading Activity Clovis Oncology Inc (NASDAQ:CLVS) – Director Sold 4,500 shares of Stock

ME Staff

7 years ago

Insider Trading Activity For Clovis Oncology Inc (NASDAQ:CLVS)

Thorlef Spickschen , Director of Clovis Oncology Inc (NASDAQ:CLVS) reportedly Sold 4,500 shares of the company’s stock at an average price of 60 for a total transaction amount of $270,000.00 SEC Form

Insider Trading History For Clovis Oncology Inc (NASDAQ:CLVS)

On 8/16/2012 Edward J Mckinley, Director, bought 9,701 with an average share price of $15.50 per share and the total transaction amounting to $150,365.50.

On 3/6/2013 Parters Vii L P Domain, Major Shareholder, sold 250,000 with an average share price of $24.59 per share and the total transaction amounting to $6,147,500.00.

On 6/4/2013 Steven L Hoerter, Insider, sold 10,000 with an average share price of $73.06 per share and the total transaction amounting to $730,600.00.

On 6/4/2013 Parters Vii L P Domain, Major Shareholder, sold 159,192 with an average share price of $64.58 per share and the total transaction amounting to $10,280,619.36.

On 6/4/2013 M James Barrett, Director, sold 2,483 with an average share price of $70.80 per share and the total transaction amounting to $175,796.40.

On 6/5/2013 Andrew R Allen, Insider, sold 22,594 with an average share price of $68.54 per share and the total transaction amounting to $1,548,592.76.

On 12/5/2013 Thorlef Spickschen, Director, sold 9,000 with an average share price of $56.10 per share and the total transaction amounting to $504,900.00.

Analyst Ratings History For Clovis Oncology Inc (NASDAQ:CLVS)

On 8/24/2016 Mizuho Boost Price Target of rating Neutral with a price target of $15.00 to $23.00
On 12/21/2016 WallachBeth Capital Boost Price Target of rating Hold with a price target of $22.00 to $49.00
On 3/28/2017 Piper Jaffray Companies Set Price Target of rating Buy with a price target of $77.00
On 6/19/2017 Chardan Capital Upgraded rating Sell to Neutral with a price target of $36.00 to $50.00
On 6/20/2017 Janney Montgomery Scott Upgraded rating Neutral to Buy
On 6/20/2017 Goldman Sachs Group Reiterated Rating Neutral with a price target of $67.00 to $90.00
On 6/22/2017 SunTrust Banks Reiterated Rating Buy

Recent Trading Activity for Clovis Oncology Inc (NASDAQ:CLVS)
Shares of Clovis Oncology Inc closed the previous trading session at with shares trading hands.